Viewing Study NCT07024732


Ignite Creation Date: 2025-12-24 @ 9:42 PM
Ignite Modification Date: 2025-12-30 @ 8:08 AM
Study NCT ID: NCT07024732
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-06-17
First Post: 2025-06-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
Sponsor: Eyevensys
Organization:

Study Overview

Official Title: An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).

The main question it aims to answer is: Is PST-611-CT1 safe for participants?

Participants will:

* Receive a single dose of PST-611
* Will be followed up for a total of 16 weeks following PST-611 administration
Detailed Description: The maximum study duration per patient is 28 Weeks (including an up to 12 week screening period + 16 weeks of follow-up after treatment).

The study is a single ascending dose study that investigates two PST-611 dose levels (low and high doses) in 2 successive dose groups. The study will enroll up to 12 participants.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2024-519025-37-00 CTIS None View